Clinical Trials on Nasal Congestion in Japan

Total 119 results

AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, United Kingdom, Sweden
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

United States, Austria, Czech Republic, Finland, France, Germany, Hungary, India, Japan, Malaysia, Netherlands, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
AbbVie

Terminated

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

United States, Australia, Canada, Italy, Japan
Boehringer Ingelheim

Completed

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Japan
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
Boehringer Ingelheim

Completed

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Special Survey on PD Patients With Renal Dysfunction

Parkinson Disease

Japan
AbbVie

Active, not recruiting

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

Parkinson's Disease

Japan
AbbVie

Terminated

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States, Australia, Canada, France, Germany, Italy, Japan, Spain
Eisai Inc.

Completed

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, Spain, France, Germany, Italy, Japan, United Kingdom
Boehringer Ingelheim

Completed

Survey on PD Patients With Depressive Symptoms

Parkinson Disease

Japan
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Eisai Co., Ltd.

Completed

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Dementia With Lewy Bodies (DLB)

Japan
Alexion Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Wilson Disease

United States, Spain, Taiwan, France, Czechia, Hungary, Turkey, United Kingdom, Austria, Germany, Israel, Serbia, Australia, Japan, Denmark, Korea, Republic of, New Zealand, Canada, Russian Federation, Poland, Singapore, Hong Kong
Takeda
AstraZeneca

Recruiting

A Study of TAK-341 in Treatment of Multiple System Atrophy

Multiple System Atrophy

Spain, Germany, United States, Italy, United Kingdom, Austria, Denmark, France, Japan, Portugal
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Huntingtons Disease

United States, United Kingdom, Australia, Canada, Japan, Poland, Netherlands, Germany, Russian Federation, France, Spain, Argentina, New Zealand, Austria, Denmark, Italy, Switzerland, Chile

Clinical Trials on Nasal Congestion in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations